Argus Research Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $400
United Therapeutics Is Maintained at Buy by Argus Research
Jefferies Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $432
United Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $425
A Quick Look at Today's Ratings for United Therapeutics(UTHR.US), With a Forecast Between $395 to $600
J.P. Morgan Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $360
United Therapeutics Is Maintained at Buy by TD Cowen
United Therapeutics Analyst Ratings
TD Cowen Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $400
Jefferies Initiates United Therapeutics(UTHR.US) With Buy Rating, Announces Target Price $432
Jefferies Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $432
United Therapeutics Analyst Ratings
Oppenheimer Maintains Outperform on United Therapeutics, Raises Price Target to $575
United Therapeutics Analyst Ratings
Oppenheimer Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $575
Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $375
Morgan Stanley Maintains United Therapeutics(UTHR.US) With Hold Rating, Maintains Target Price $337
United Therapeutics Analyst Ratings
Wells Fargo Maintains Overweight on United Therapeutics, Raises Price Target to $380
No Data
No Data